Cetuximab: An IgG1 monoclonal antibody for the treatment of epidermal growth factor receptor-expressing tumours

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 7, 2004, Pages 1621-1633

  Humblet, Yves ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Cetuximab; EGFR expressing tumours; Epidermal growth factor receptor; Erbitux; Monoclonal antibody

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IMMUNOGLOBULIN G1; IRINOTECAN; MATUZUMAB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 4D5; NAVELBINE; PACLITAXEL; PANITUMUMAB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; TOPOTECAN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACNE; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; CANCER CELL; CELL DIFFERENTIATION; CELL GROWTH; CELL SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DEHYDRATION; DIARRHEA; DISEASE EXACERBATION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPNEA; HAIR LOSS; HEAD AND NECK CANCER; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; METASTASIS; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NONHUMAN; PAIN; PROGNOSIS; PROTEIN EXPRESSION; RASH; SIDE EFFECT; SKIN MANIFESTATION; SWITZERLAND; UNITED STATES; VOMITING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GENE EXPRESSION; GENES, ERBB-1; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOGLOBULIN G; LUNG NEOPLASMS; MALE; MICE; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 3543065879     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.7.1621     Document Type: Article

References (93)

1. DE LARCO JE, TODARO GJ: Epithelioid and fibroblastic rat kidney cell clones: epidermal growth factor (EGF) receptors and the effect of mouse sarcoma virus transformation. J. Cell. Physiol. (1978) 94:335-342.
2. CUNNINGHAM D, HUMBLET Y, SIENA S et al.: Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with Epidermal Growth Factor Receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC). Proc. Am. Soc. Clin. Oncol. (2003) 22:Abstract 1012.
3. SPANO J-P, ATLAN D, GLAGORCE C et al.: Correlation of EGFR expression and other tumor characteristics in colorectal cancer outcome and prognosis. Ann. Oncol. (2002) 13(Suppl. 5):72.
4. ROSELL R, RAMLAU R, SZCZESNA A et al.: Randomized Phase II clinical trial of cetuximab in combination with cisplatin (C) and vinorelbine (V) or CV alone in patients with advanced Epidermal Growth Factor Receptor (EGFR)-expressing non-small-cell lung cancer (NSCLC). Eur. J. Cancer (2003) 1(Suppl. 5):S21.
5. SELVAGGI G, NOVELLO S, TORRI V et al.: Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Ann. Oncol. (2004) 15:28-32.
6. O-CHAROENRAT P, RHYS-EVANS PH, ARCHER DJ, ECCLES SA: C-erbB receptors in squamous cell carcinomas of the head and neck: clinical significance and correlation with matrix metalloproteinases and vascular endothelial growth factors. Oral Oncol. (2002) 38:73-80.
7. NUMICO G, COLANTONIO I, COMINO A et al.: EGFR and survival of patients with locally advanced head and neck cancer (HNC) and treated with alternating chemotherapy radiation (CT-RT). Results of a retrospective analysis. Proc. Am. Soc. Clin. Oncol. (2003) 22:Abstract 2018.
8. HITT R, CASTELLANO D, CIRUELOS E et al.: Overexpression of epidermal growth factor receptor (EGFR) and p53 mutations levels as prognostic factors in patients with locally-advanced head and neck cancer (LAHNC) treated with induction chemotherapy. Proc. Am. Soc. Clin. Oncol. (2002) 21:Abstract 972.
9. KHORANA AA, RYAN CK, COX C, SAHASRABUDHE DM: EGFR and VEGF expression in primary colon tumors as predictors of survival in stage II and III colon cancer. Proc. Am. Soc. Clin. Oncol. (2002) 21:Abstract 2395.
10. NICHOLSON RI, GEE JM, HARPER ME: EGFR and cancer prognosis. Eur. J. Cancer (2001) 37(Suppl. 4):S9-S15.
11. WIKSTRAND CJ, MCLENDON RE, FRIEDMAN AH, BIGNER DD: Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res. (1997) 57:4130-4140.
12. PAEZ JG, JANNE PA, LEE JC et al.: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 304(5676):1497-1500.
13. LYNCH TJ, BELL DW, SORDELLA R et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. (2004) 350:2129-2139.
14. HERBST RS, SHIN DM: Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer (2002) 94:1593-1611.
15. GOLDSTEIN NI, PREWETT M, ZUKLYS K, ROCKWELL P, MENDELSOHN J: Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res. (1995) 1:1311-1318.
16. FAN Z, LU Y, WU X, MENDELSOHN J: Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J. Biol. Chem. (1994) 269:27595-27602.
17. MEROPOL NJ, BERLIN J, HECHT JR et al.: Multicenter study of ABX-EGF monotherapy in patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. (2003) 22:Abstract 1026.
18. VANHOEFER U, TEWES M, ROJO F et al.: Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J. Clin. Oncol. (2004) 22:175-184.
19. KOLLMANNSBERGER C, SCHITTENHELM M, HONECKER F et al.: Epidermal growth factor receptor (EGFR) antibody EMD 72000 in combination with paclitaxel (P) in patients (pts) with EGFR-positive advanced non-small cell lung cancer (NSCLC): a phase-I study. Proc. Am. Soc. Clin. Oncol. (2003) 22:Abstract 2520.
20. WINQUIST E, NABID A, SICHERI D et al.: A Phase I dose escalation study of a humanized monoclonal antibody to EGFR (hR3) in patients with locally advanced squamous cell cancer of the head and neck (SCCHN) treated with radiotherapy (RT). Proc. Am. Soc. Clin. Oncol. (2002) 21:Abstract 926.
21. COHEN MH, WILLIAMS GA, SRIDHARA R et al.: United States Food and Drug Administration Drug Approval summary: gefitinib (ZD1839; Iressa) tablets. Clin. Cancer Res. (2004) 10:1212-1218.
22. OZA AM, TOWNSLEY CA, SIU LL et al.: Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. (2003) 22:Abstract 785.
23. KIYOTA A, SHINTANI S, MIHARA M et al.: Anti-epidermal growth factor receptor monoclonal antibody 225 upregulates p27(KIP1) and p15 (INK4B) and induces G1 arrest in oral squamous carcinoma cell lines. Oncology (2002) 63:92-98.
24. PENG D, FAN Z, LU Y et al.: Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Res. (1996) 56:3666-3669.
25. WU X, FAN Z, MASUI H, ROSEN N, MENDELSOHN J: Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J. Clin. Invest. (1995) 95:1897-1905.
26. KARASHIMA T, SWEENEY P, SLATON JW et al.: Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice. Clin. Cancer Res. (2002) 8:1253-1264.
27. PERROTTE P, MATSUMOTO T, INOUE K et al.: Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin. Cancer Res. (1999) 5:257-265.
28. NARAMURA M, GILLIES SD, MENDELSOHN J, REISFELD RA, MUELLER BM: Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma. Cancer Immunol. Immunother. (1993) 37:343-349.
29. PREWETT MC, HOOPER AT, BASSI R et al.: Enhanced antitumor activity of antiepidermal growth fictor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin. Cancer Res. (2002) 8:994-1003.
30. PREWETT M, HOOPER A, BASSI R et al.: Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody cetuximab (IMC-C225) in combination with irinotecan (CPT-11), 5-FU, and leucovorin against human colorectal carcinoma xenografts. Eur. J. Cancer (2002) 38(Suppl. 7):Abstract 501.
31. SUN H, PYTOWSKI B, HOOPER A et al.: Epidermal growth factor receptor antibody cetuximab inhibits irinotecan-induced up-regulation of mitogen activated protein kinase phosphorylation: a possible mechanism for the enhanced effects in combination therapy of colorectal tumors. American Society of Clinical Oncology Gastrointestinal Cancers Symposium (2004):Abstract 280.
32. CLARDIELLO F, BLANCO R, DAMIANO V et al.: Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin. Cancer Res. (1999) 5:909-916.
33. PREWETT M, HOOPER A, BASSI R et al.: Growth inhibition of human colorectal carcinoma xenografts by anti-EGF receptor monoclonal antibody IMC-C225 in combination with 5-fluorouracil or irinotecan. Proc. Am. Assoc. Cancer. Res. (2001) 42:Abstract 1543.
34. INOUE K, SLATON JW, PERROTTE P et al.: Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin. Cancer Res. (2000) 6:4874-4884.
35. PREWETT M, ROCKWELL P, ROSE C, GOLDSTEIN NI: Anti-tumor and cell cycle responses in KB cells treated with a chimeric anti-EGFR monoclonal antibody in combination with cisplatin. Int. J. Oncol. (1996) 9:217-224.
36. BASELGA J, NORTON L, MASUI H et al.: Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J. Natl. Cancer Inst. (1993) 85:1327-1333.
37. BRUNS CJ, HARBISON MT, DAVIS DW et al.: Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin. Cancer Res. (2000) 6:1936-1948.
38. RABEN D, HELFRICH B, CHAN DT et al.: C225 anti-EGFR antibody potentiates radiation (RT) and chemotherapy (CT) cytotoxicity in human non-small cell lung cancer (NSCLC) cells in vitro and in vivo. Proc. Am. Soc. Clin. Oncol. (2001) 20:Abstract 1026.
39. MILAS L, MASON K, HUNTER N et al.: In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin. Cancer Res. (2000) 6:701-708.
40. BUCHSBAUM DJ, BONNER JA, GRIZZLE WE et al.: Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine and radiation. Int. J. Radiat. Oncol. Biol. Phys. (2002) 54:1180-1193.
41. HUANG S-M, ARMSTRONG E, CHINNAIYAN P, HARARI PM: Dual agent molecular targeting of the epidermal growth factor receptor: Combining anti-HER1/EGFR monoclonal antibody with tyrosine kinase inhibitor. Proc. Am. Assoc. Cancer Res. (2003) 44:Abstract 3777.
42. YE D, MENDELSOHN J, FAN Z: Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225. Oncogene (1999) 18:731-738.
43. YAMASHITA Y, YAMAZAKI M, OHIRA M et al.: Anti-receptor signaling strategy in esophageal carcinoma: Double targeting against egfr and her. Proc. Am. Assoc. Cancer Res. (2004) 45:Abstract 5351.
44. MERCK: Data on file, Merck KGaA.
45. FOX FE, MAURO D, BAI S et al.: A population pharmacokinetic (PPK) analysis of the anti-EGFr specific IgG1 monoclonal antibody cetuximab. American Society of Clinical Oncology Gastrointestinal Cancers Symposium (2004) Abstract 290.
46. FOLPRECHT G, LUTZ MP, SCHOEFFSKI P et al.: Pharmacokinetic (PK) evaluation of cetuximab in combination with weekly irinotecan (CPT-11) and 24h infusional 5-FU/folinic acid (FA) as first line treatment in patients (pts) with epidermal growth factor receptor (EGFR)-positive metastatic colorectal cancer (MCRC). Proc. Am. Soc. Clin. Oncol. (2003) 22:Abstract 890.
47. DELBALDO C, PIERGA JY, DIERAS V et al.: Evaluation of the pharmacokinetic (PK) interaction between cetuximab and irinotecan in patients with epidermal growth factor receptor (EGFR)-expressing advanced solid tumors. Results of a Phase I study. Eur.J. Cancer Suppl. (2003) 1(5):Abstract 552.
48. BASELGA J, PFISTER D, COOPER MR et al.: Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J. Clin. Oncol. (2000) 18:904-914.
49. PARKIN DM, PISANI P, FERLAY J: Global cancer statistics. CA Cancer J. Clin. (1999) 49:33-64.
50. CUNNINGHAM D, FINDLAY M: The chemotherapy of colon cancer can no longer be ignored. Eur. J. Cancer (1993) 29A:2077-2079.
51. HOBDAY TJ, CHA SS, SARGENT DJ et al.: Long term survivors (LTS) of metastatic colorectal cancer (MCRC) treated with chemotherapy only: a North Central Cancer Treatment Group (NCCTG) review. Proc. Am. Soc. Clin. Oncol. (2002) 21:Abstract 693.
52. SALTZ LB, COX JV, BLANKE C et al.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med. (2000) 343:905-914.
53. DOUILLARD JY, CUNNINGHAM D, ROTH AD et al.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet (2000) 355:1041-1047.
54. GOLDBERG RM, SARGENT DJ, MORANT RS et al.: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. (2004) 22:23-30.
55. TOURNIGAND C, ANDRE T, ACHILLE E et al.: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomised GERCOR study. J. Clin. Oncol. (2004) 22:229-237.
56. VANHOEFER U, HARSTRICK A, ACHTERRATH W et al.: Irinotecan in the treatment of colorectal cancer: clinical overview. J. Clin. Oncol. (2001) 19:1501-1518.
57. ROTHENBERG ML, OZA AM, BURGER B et al.: Final results of a Phase III trial of 5-FU/leucovorin versus oxaliplatin versus the combination in patients with metastatic colorectal cancer following irinotecan, 5-FU, and leucovorin. Proc. Am. Soc. Clin. Oncol. (2003) 22:Abstract 2003.
58. SALTZ L, RUBIN M, HOCHSTER H et al.: Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc. Am. Soc. Clin. Oncol. (2001) 20:Abstract 7.
59. SALTZ L, MEROPOL NJ, LOEHRER PJ et al.: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. (2004) 22(7):1201-1208.
60. BENSMAINE MA, MARTY M, DE GRAMONT A et al.: Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) +/- folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients. Br. J. Cancer (2001) 85:509-517.
61. LENZ HJ, MAYER RJ, GOLD P et al.: Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. Proc. Am. Soc. Clin. Oncol. (2004) 23:Abstract 3510.
62. ROSENBERG AH, LOEHRER PJ, NEEDLE MN et al.: Erbitux (IMC-C225) plus weekly irinotecan (CPT-11), fluorouracil (5FU) and leucovorin (LV) in colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFr). Proc. Am. Soc. Clin. Oncol. (2002) 21:abstract 536.
63. FOLPRECHT G, LUTZ M, SCHOEFFSKI P et al.: Cetuximab/irinotecan/high-dose-5-fluorouracil/leucovorin (HD-5-FU/LV) in the first-line therapy of metastatic colorectal cancer (CRC). American Society of Clinical Oncology Gastrointestinal Cancers Symposium (2004):Abstract 283.
64. RAOUL JL, VAN LAETHEM J-L, MITRY E et al.: Phase II study of cetuximab combined with FOLFIRI (bi-weekly irinotecan plus infusional 5-FU and folinic acid (FA)) in patients (pis) with metastatic epidermal growth factor receptor (EGFR)-expressing colorectal cancer (CRC). Eur. J. Cancer Supplements (2003) 1:Abstract S89.
65. HURWITZ H, FEHRENBACHER L, CARTWRIGHT T et al.: Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): Results of a Phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Proc. Am. Soc. Clin. Oncol. (2003) 22:Abstract 3646.
66. GIANTONIO BJ, LEVY D, O'DWYER PJ et al.: Bevacizumab (anti-VEGF) plus IFL (irinotecan, fluorouracil, leucovorin) as front-line therapy for advanced colorectal cancer (advCRC): updated results from the Eastern Cooperative Oncology Group (ECOG) Study E2200. www.asco.org. Gastrointestinal Cancers Symposium (2004) Abstract 289.
67. IRO H, WALDFAHRER F: Evaluation of the newly updated TNM classification of head and neck carcinoma with data from 3247 patients. Cancer (1998) 83:2201-2207.
68. PIVOT X: ESMO Minimum clinical recommendations for diagnosis, treatment and follow-up of squamous cell carcinoma of the head and neck. Ann. Oncol. (2003) 14:1014-1015.
69. KOWALSKI LP, CARVALHO AL: Natural history of untreated head and neck cancer. Eur. J. Cancer (2000) 36:1032-1037.
70. LEON X, HITT R, CONSTENLA M et al.: A retrospective analysis of the outcome of patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R&M SCCHN) who are progressing while on a platinum-based palliative chemotherapy. Proc. Am. Soc. Clin. Oncol. (2003) 22:Abstract 2022.
71. KIES MS, ARQUETTE MA, NABELL L et al.: Final report of the efficacy and safety of the anti-epidermal growth factor antibody Erbitux (IMC-C225), in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy. Proc. Am. Soc. Clin. Oncol. (2002) 21:Abstract 925.
72. BASELGA J, TRIGO JM, BOURHIS J et al.: Cetuximab (C225) plus cisplatin/carboplatin is active in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCNH) progressing on a same dose and schedule platinum-based regimen. Proc. Am. Soc. Clin. Oncol. (2002) 21:Abstract 900.
73. CHAN ATC, HSU MM, GOH BC et al.: A Phase II study of cetuximab (C225) in combination with carboplatin in patients (pts) with recurrent or metastatic nasopharyngeal carcinoma (NPC) who faded to a platinum-based chemotherapy. Proc. Am. Soc. Clin. Oncol. (2003) 22:Abstract 2000.
74. TRIGO J, HITT R, KORALEWSKI P et al.: Cetuximab (Erbitux™) monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN). Proc. Am. Soc. Clin. Oncol. (2004) 23:Abstract 5502.
75. BURTNESS BA, LI Y, FLOOD W, MATTAR BI, FORASTIERE A: Phase III randomized trial of cisplatin + placebo versus cisplatin + C225, a monoclonal antibody directed to the epidermal growth factor-receptor: an Eastern Cooperative Oncology Group trial. Clin. Cancer Res. (2003) 9(Suppl.):Abstract 77.
76. BOURHIS J, RIVERA F, MESIA R et al.: Phase I study of cetuximab (C225) in combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R&M SCCHN). Eur. J. Cancer Suppl. (2003) 1(5):S34.
77. ROBERT F, EZEKIEL MP, SPENCER SA et al.: Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J. Clin. Oncol. (2001) 19:3234-3243.
78. PFISTER DG, ALIFF TB, KRAUS DH et al.: Concurrent cetuximab, cisplatin, and concomitant boost radiation therapy (RT) for locoregionally advanced, squamous cell head and neck cancer (SCCHN): Preliminary evaluation of a new combined-modality paradigm. Proc. Am. Soc. Clin. Oncol. (2003) 22:Abstract 1993.
79. HARARI PM, CHINNAIYAN P, DURLAND W et al.: Surgical wound healing in advanced head and neck cancer patients undergoing neck dissection following high dose radiation +/- cetuximab. Int. J. Radiat. Oncol. Biol. Phys. (2003) 57:S245-S246.
80. PARKIN DM: Global cancer statistics in the year 2000. Lancet Oncol. (2001) 2:533-543.
81. KIM ES, MAUER AM, TRAN HT et al.: A Phase II study of cetuximab, an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer: Final report. Proc. Am. Soc. Clin. Oncol. (2003) 22:Abstract 2581.
82. KELLY K, HANNA N, ROSENBERG A, BUNN PA, NEEDLE MN: A multi-centered Phase I/II study of cetuximab in combination with paclitaxel and carboplatin in untreated patients with stage IV non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. (2003) 22:Abstract 2592.
83. ROBERT F, BLUMENSCHEIN G, DICKE K et al.: Phase Ib/IIa study of anti-epidermal growth factor receptor (EGFR) antibody, cetuximab, in combination with gemcitabine/carboplatin in patients with advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. (2003) 22:Abstract 2587.
84. ABBRUZZESE JL, ROSENBERG A, XIONG Q et al.: Phase II study of anti-epidermal growth factor receptor (EGFR) antibody cetuximab (IMC-C225) in combination with genicitabine in patients with advanced pancreatic cancer. Proc. Am. Soc. Clin. Oncol. (2001) 20:Abstract 518.
85. O'DWYER PJ, BENSON AB 3rd: Epidermal growth factor receptor-targeted therapy in colorectal cancer. Semin. Oncol. (2002) 29:10-17.
86. GUSTAFSON NF, SALTZ L, CUNNINGHAM D et al.: Safety profile of cetuximab in patients with metastatic colorectal cancer. American Society of Clinical Oncology Gastrointestinal Cancers Symposium (2004):Abstract 237.
87. NEEDLE MN: Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody. Semin. Oncol. (2002) 29:55-60.
88. HOLLYWOOD E: Clinical issues in the administration ofan anti-epidermal growth factor receptor monoclonal antibody, IMC-C225. Semin. Oncol. Nurs. (2002) 18:30-35.
89. COHEN RB, FALCEY JW, PAULTER VJ, FETZER KM, WAKSAL HW: Safety profile of the monoclonal antibody (MoAb) IMC-C225, an anti-epidermal growth factor receptor (EGFR) used in the treatment of EGFR-positive tumors. Proc. Am. Soc. Clin. Oncol. (2000) 19:Abstract 1862.
90. BUSAM KJ, CAPODIECI P, MOTZER R et al.: Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br. J. Dermatol. (2001) 144:1169-1176.
91. SALTZ L, KIES M, ABBRUZZESE JL, AZARNIA N, NEEDLE M: The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc. Am. Soc. Clin. Oncol. (2003) 22:Abstract 817.
92. KHAZAELI MB, LOSSUGLIO AF, FALCEY JW et al.: Low immunogenicity of a chimeric monoclonal antibody (MoAb), IMC-C225, used to treat epidermal growth factor receptor-positive tumors. Proc. Am. Soc. Clin. Oncol. (2000) 19:Abstract 808.
93. KIM ES, KHURI FR, HERBST RS: Epidermal growth factor receptor biology (IMC-C225). Curr. Opin. Oncol. (2001) 13:506-513.